Group One Trading
SPRO icon

Group One Trading’s Spero Therapeutics SPRO Stock Holding History

Group One Trading’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86K Buy
38,900
+20,500
+111% +$53.6K ﹤0.01% 4982
2026
Q1 		$43.1K Sell
18,400
-93,400
-84% -$222K ﹤0.01% 5375
2025
Q4 		$260K Buy
111,800
+23,300
+26% +$54.1K ﹤0.01% 4131
2025
Q3 		$166K Sell
88,500
-22,900
-21% -$50.4K ﹤0.01% 4873
2025
Q2 		$323K Buy
+111,400
New +$160K ﹤0.01% 3847
2024
Q3 		– Sell
-6,500
Closed -$8.45K – 7329
2024
Q2 		$8.45K Hold
6,500
– – ﹤0.01% 5717
2024
Q1 		$11.2K Buy
+6,500
New +$10.2K ﹤0.01% 5812
2023
Q3 		– Sell
-17,000
Closed -$24.6K – 8253
2023
Q2 		$24.6K Buy
17,000
+10,400
+158% +$17.8K ﹤0.01% 5831
2023
Q1 		$9.57K Sell
6,600
-83,200
-93% -$139K ﹤0.01% 5959
2022
Q4 		$155K Buy
89,800
+48,100
+115% +$89.8K ﹤0.01% 4071
2022
Q3 		$83K Buy
41,700
+34,900
+513% +$34.7K ﹤0.01% 4946
2022
Q2 		$5K Buy
6,800
+1,800
+36% +$5.23K ﹤0.01% 7127
2022
Q1 		$44K Buy
5,000
+4,800
+2,400% +$49.2K ﹤0.01% 6189
2021
Q4 		$3K Sell
200
-29,900
-99% -$475K ﹤0.01% 7811
2021
Q3 		$554K Buy
30,100
+8,500
+39% +$136K ﹤0.01% 4070
2021
Q2 		$302K Buy
21,600
+14,700
+213% +$205K ﹤0.01% 4781
2021
Q1 		$102K Buy
6,900
+6,700
+3,350% +$118K ﹤0.01% 5643
2020
Q4 		$4K Sell
200
-800
-80% -$12.5K ﹤0.01% 6112
2020
Q3 		$11K Hold
1,000
– – ﹤0.01% 5389
2020
Q2 		$14K Buy
+1,000
New +$11.2K ﹤0.01% 5001

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Group One Trading's SPRO Position: Q2 2026 in Review

Group One Trading opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 10,869 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #5892 among its holdings. This is a return to the name: Group One Trading previously reported a position in SPRO as recently as Q3 2025.

Group One Trading first reported a position in SPRO in Q4 2018 and has held it in 16 quarters since. The position peaked at $133K in Q2 2023. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Group One Trading held 10,869 shares of Spero Therapeutics worth $24K as of Q2 2026.
  • Spero Therapeutics was a new Group One Trading position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5892 holding.
  • Group One Trading first reported a position in Spero Therapeutics in Q4 2018 and has held it in 16 quarters since.
  • Group One Trading's Spero Therapeutics position peaked at $133K in Q2 2023.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.